The observation that low GLO1 expression in human PDAC tumor tissue correlates with increased sensitivity to IKE suggests that assessing GLO1 expression may help identify patients suitable for ferroptosis‐targeted therapy. This evidence concerns the gene GLO1 and neoplasm.